Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

Infection and Immunity

Volumn 70, Issue 12, 2002, Pages 6697-6706

  Afrin, Farhat ^a,b   Rajesh, Ravindran ^a   Anam, Khairul ^a,c   Gopinath, Meenakshisundram ^a,d   Pal, Swati ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b HAMDARD UNIVERSITY   (India)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP 39; GLYCOPROTEIN GP 45; GLYCOPROTEIN GP 48; GLYCOPROTEIN GP 52; GLYCOPROTEIN GP 63; GLYCOPROTEIN GP 72; LIPOSOME; MEMBRANE ANTIGEN; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; IMMUNOGENICITY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES;

EID: 0036893636     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.12.6697-6706.2002     Document Type: Article

References (64)

1. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793.
2. Abdelhak, S., H. Louzir, J. Timm, L. Blel, Z. Benlasfar, H. Lagranderie, M. Gheorghiu, K. Dellagi, and B. Gicquel. 1995. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 141:1585-1592.
3. Afrin, F., and N. Ali. 1997. Adjuvanicity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 65:2371-2377.
4. Afrin, F., and N. Ali. 1998. Isotype profiles of Leishmania donovani-infected BALB/c mice: Preferential stimulation of IgG2a/b by liposome-associated promastigote antigens. J. Parasitol. 84:743-748.
5. Afrin, F., K. Anam, and N. Ali. 2000. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes. J. Parasitol. 86:730-735.
6. Ali, N., and F. Afrin. 1997. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes. J. Parasitol. 83:70-75.
7. Anam, K., F. Afrin, D. Banerjee, N. Pramanik, S. K. Guha, R. P. Goswami, P. N. Gupta, S. K. Saha, and N. Ali. 1999. Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Clin. Diagn. Lab. Immunol. 6:231-235.
8. Beyrodt, C. G. P., A. R. Pinto, E. Freymuller, and C. L. Barbieri. 1997. Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infect. Immun. 65:2052-2059.
9. Bogdan, C., A. Gesser, W. Solbach, and M. Rollinghoff. 1996. Invasion, control and persistence of Leishmania parasites. Curr. Opin. Immunol. 8:517-525.
10. Bretscher, P. A., G. Wei, J. N. Menon, and H. Bielefeldt-Ohmann. 1992. Establishment of cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257:539-542.
11. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:3272-3279.
12. Coffman, R. L., D. A. Lebman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54:229-270.
13. Connell, N. D., E. Medina-Acosta, W. R. McMaster, B. R. Bloom, and D. G. Russell. 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. USA 90:11473-11477.
14. Fargeas, C., M. Hommel, R. Maingon, C. Dourado, M. Monsigny, and R. Mayer. 1996. Synthetic peptide-based enzyme-linked immunosorbent assay for serodiagnosis of visceral leishmaniasis. J. Clin. Microbiol. 34:241-248.
15. Germann, T., M. Bongartz, H. Dlugonska, H. Hess, E. Schmitt, L. Kolbe, E. Kolsch, F. J. Podlaski, M. K. Gately, and E. Rude. 1995. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur. J. Immunol. 25:823-829.
16. Guimaraes, T. M. P. D., V. P. C. P. de Toledo, C. A. da Costa, R. T. da Costa, O. Genaro, P. Williams, and W. Maybrink. 1996. Assessment of immunity induced in mice by glycoproteins derived from different strains and species of Leishmania. Mem. Inst. Oswaldo Cruz 91:63-70.
17. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409-1415.
18. Handman, E., and G. F. Mitchell. 1985. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc. Natl. Acad. Sci. USA 82:5910-5914.
19. Handman, E., F. M. Symons, T. M. Baldwin, J. M. Curtis, and J.-P. Y. Scheerlinck. 1995. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun. 63:4261-4267.
20. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59-72.
21. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA 88:7011-7015.
22. Herwaldt, B. L. 1999. Leishmaniasis. Lancet 354:1191-1199.
23. Holbrook, J. W., and J. A. Cook. 1983. Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes. Am. J. Trop. Med. Hyg. 32:51-53.
24. Jaffe, C. L., N. Rachamim, and R. Sarfstein. 1990. Characterization of two proteins from Leishmania donovani and their use for vaccine against visceral leishmaniasis. J. Immunol. 144:699-706.
25. Jardim, A., J. Alexander, H. S. Teh, D. Qu, and R. W. Olafson. 1990. Immunoprotective Leishmania major synthetic T cell epitopes. J. Exp. Med. 172:645-648.
26. Kahl, L. P., C. A. Scott, R. Lelchuk, G. Gregoriadis, and F. Y. Liew. 1989. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. J. Immunol. 142:4441-4449.
27. Kahl, L. P., R. Lelchuk, C. A. Scott, and J. Beesley. 1990. Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis. Infect. Immun. 58:3233-3241.
28. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. H. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin 10 and interferon gamma. J. Clin. Investig. 91:1644-1648.
29. Kaye, P. M., A. J. Curry, and J. F. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763-2770.
30. Kenney, R. T., D. L. Sacks, A. A. Gam, H. W. Murray, and S. Sundar. 1998. Splenic cytokine response in Indian kala-azar before and after treatment. J. Infect. Dis. 177:815-819.
31. + T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect. Immun. 61:5205-5213.
32. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
33. Lepay, D. A., N. Noguiera, and Z. Cohn. 1983. Surface antigens of Leishmania donovani promastigotes. J. Exp. Med. 157:1562-1572.
34. - T cells that do not mediate cutaneous DTH. J. Immunol. 132:456-461.
35. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
36. McSorley, S. J., D. Xu, and F. Y. Liew. 1997. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect. Immun. 65:171-178.
37. Medina-Acosta, E., R. E. Karess, and D. G. Russell. 1993. Structurally distinct genes for the surface protease of Leishmania mexicana are developmentally regulated. Mol. Biochem. Parasitol. 57:31-46.
38. Medrano, F. J., C. Canavate, M. Leal, C. Rey, E. Lissen, and J. Alvar. 1998. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with immunodeficiency virus type-1. Am. J. Trop. Med. Hyg. 59:155-162.
39. Melby, P. C., J. Yang, W. Zhao, L. E. Pervez, and J. Cheng. 2001. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
40. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994. Th1 and Th2 cell-associated cytokines in experimental leishmaniasis. Infect. Immun. 62:1058-1063.
41. Modabber, F. 1993. Leishmaniasis, p. 77-87. In UNDP/World Bank/ W. H. O. Special Programme for Research and Training in Tropical Diseases, Tropical Disease Research: 11th Programme Report. World Health Organization, Geneva, Switzerland.
42. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppala, Z.-E. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
43. Okong'o-Odera, E. A., J. A. L. Kurtzhals, A. S. Hey, and A. Kharazmi. 1993. Measurement of serum antibodies against native Leishmania gp63 distinguishes between ongoing and previous Leishmania donovani infection. APMIS 101:642-646.
44. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
45. Reed, S. G., and P. Scott. 1993. T-cell and cytokine response in leishmaniasis. Curr. Opin. Immunol. 5:524-531.
46. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177.
47. Reiner, S. L., Z.-E. Wang, F. Hatam, P. Scott, and R. M. Locksley. 1993. Th1 and Th2 cell antigen receptors in experimental leishmaniasis. Science 259:1457-1460.
48. Rivier, D., P. Bovay, R. Shah, S. Didisheim, and J. Mauel. 1999. Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection. Parasite Immunol. 21:461-473.
49. Rolland-Burger, L., X. Rolland, C. W. Grieve, and L. Monjour. 1991. Immunoblot analysis of the humoral immune response to Leishmania donovani infantum polypeptides in human visceral leishmaniasis. J. Clin. Microbiol. 29:1429-1435.
50. Rosenthal, E., P. Marty, I. Poizot-Martin, J. Reynes, F. Pratlong, A. Lafeuillade, D. Jaubert, O. Boulat, J. Dereure, F. Gambarelli, J. A. Gastant, P. Dujardin, P. Dellamonica, and J. P. Cassuto. 1995. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. R. Soc. Trop. Med. Hyg. 89:159-162.
51. Russell, D. G., and J. Alexander. 1988. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 140:1274-1279.
52. Schreffler, W. G., J. M. Burns, Jr., R. Badaro, H. W. Ghalib, L. L. Button, W. R. McMaster, and S. G. Reed. 1993. Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species. J. Infect. Dis. 167:426-430.
53. Scott, P., E. Pearce, P. Natovitz, and A. Sher. 1987. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with soluble extract of promastigotes. J. Immunol. 139:221-227.
54. Sharifi, I., A. R. Fekri, M.-R. Aflatonian, A. Khamesipour, A. Nadim, M.-R. A. Mousavi, A. Z. Momeni, Y. Dowlati, T. Godal, F. Zicker, P. G. Smith, and F. Modabber. 1998. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351:1540-1543.
55. Sjolander, A., T. M. Baldwin, J. M. Curtis, and E. Handman. 1998. Induction of Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
56. Soong, L., M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
57. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight day method for screening compounds against Leishmania donovani in golden hamster. J. Protozool. 5:269-273.
58. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.
59. Webb, J. R., W. Kaufmann, A. Campos-Neto, and S. G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.
60. Wilson, M. E., B. M. Young, K. P. Andersen, J. V. Weinstock, A. Metwali, K. M. Ali, and J. E. Donelson. 1995. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect. Immun. 63:2062-2069.
61. Wray, W., T. Boulikas, V. P. Wray, and R. Hancock. 1981. Silver staining of proteins in polyacrylamide gels. Anal. Biochem. 118:197-203.
62. Xu, D., and F. Y. Liew. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63 of L. major. Immunology 84:173-176.
63. Yang, D. M., M. V. Rogers, and F. Y. Liew. 1991. Identification and characterization of host protective T cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology 72:3-9.
64. -) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 145:2281-2285.